Underperformance of EU medtech industry overseers pinpointed in joint assessment initiative
This article was originally published in SRA
Executive Summary
Several EU regulatory authorities responsible for the designation of medical device notified bodies changed their processes following a two-year voluntary initiative that identified problems – dubbed "opportunities for improvement" in a European Commission report– in the way they work1. Among other things, the initiative highlighted shortcomings related to the planning, scope and depth of surveillance assessments undertaken by NB designation authorities during this period.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.